Less than two months after Pfizer opted to give up its rights to late-stage Sangamo Therapeutics-partnered hemophilia A gene therapy candidate giroctocogene fitelparvovec, the big pharma has decided to end development and commercialization of Beqvez (fidanacogene elaparvovec-dzkt), its hemophilia B gene therapy approved in the US in April 2024. The company told Scrip that it does not plan to develop or commercialize any other adeno-associated virus (AAV)-based gene therapies.
Pfizer Cuts Last AAV Gene Therapy Program By Taking Beqvez Off The Market
Product Saw Zero Sales Since April Approval
Pfizer cited many reasons for ending sales of hemophilia B gene therapy Beqvez, including a lack of patient and doctor interest. The company no longer plans to develop AAV gene therapies.
